Cidara Therapeutics, Inc.
CDTXDelisted Jan 7, 2026- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001610618
Cidara Therapeutics, Inc. was delisted on Jan 7, 2026; its insiders filed their last Form 4 on Jan 9, 2026; 255 institutions reported holding it in 13F filings for Q4 2025, worth $7.36B in total; 3 superinvestors held it, including Maverick Capital and Soros Fund Management.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Cidara Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Cidara Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| RA Capital Healthcare Fund LP | Director, 10% Owner | 0Indirect | Jan 9, 2026 | 1 |
| Ra Capital Management, L.P. | Director, 10% Owner | 0Indirect | Jan 9, 2026 | 1 |
| Kolchinsky Peter | Director, 10% Owner | 0Indirect | Jan 9, 2026 | 1 |
| Shah Rajeev M. | Director, 10% Owner | 0Indirect | Jan 9, 2026 | 1 |
| Burgess Daniel D | Director | 0Indirect | Jan 7, 2026 | 1 |
| Karbe Frank | Chief Financial Officer | 0 | Jan 7, 2026 | 2 |
| Schroeder Theodore R | Director | – | Jan 7, 2026 | 1 |
| Stein Jeffrey | President & CEO | 0Indirect | Jan 7, 2026 | 4 |
| Mineo Chrysa | Director | 0 | Jan 7, 2026 | 1 |
| Ward Shane | COO & CLO | 0 | Jan 7, 2026 | 2 |
| Bassler Bonnie L | Director | 0 | Jan 7, 2026 | 1 |
| Resnick Joshua | Director | – | Jan 7, 2026 | 1 |
| Spencer Ryan | Director | – | Jan 7, 2026 | 1 |
| Canale-Theakston Carin | Director | – | Jan 7, 2026 | 1 |
| Merson James | Director | – | Jan 7, 2026 | 1 |
| Davarpanah Nicole Negar | Chief Medical Officer | 0 | Jan 7, 2026 | 3 |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER | 16,215 | Mar 13, 2025 | 0 |
| Sandison Taylor | Chief Medical Officer | 23,067 | Oct 2, 2024 | 0 |
| Shah Preetam | Chief Financial Officer | 335,960 | Oct 2, 2024 | 0 |
| Tadvalkar Laura | Director | – | Jul 19, 2024 | 0 |
| Franson Timothy R | Director | 11,000 | Jun 23, 2023 | 0 |
| Gollaher David L | Director | – | Jun 23, 2023 | 0 |
| Daruwala Paul | Chief Operating Officer | 221,099 | Sep 13, 2022 | 0 |
| Johnson Brady | Vice President, Finance | 59,366 | Apr 4, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 7, 2026 (view filing) | Mar 31, 2017-Nov 10, 2020 | 3,204 daysLate | Stein JeffreyPresident & CEO | PPurchase | +4.26K | $79.55 | +$339.1K | +6.5%69.4K after | 4 lots |
| Dec 12, 2025 (view filing) | Dec 10 | 2 days | Ward ShaneCOO & CLO | SSale | −9.96K | $220.08 | −$2.19M | −28.5%25.0K after | |
| Sep 15, 2025 (view filing) | Sep 11 | 4 days | Davarpanah Nicole NegarChief Medical Officer | SSale | −474 | $62.86 | −$29.8K | −1.5%31.4K after | |
| Jun 30, 2025 (view filing)4:56 PM ET | Jun 26 | 4 days | RA Capital Healthcare Fund LP and 3 othersDirector, 10% Owner | PPurchase | +2.27M | $44.00 | +$100.0M | +208.0%3.37M after | |
| Jun 4, 2025 (view filing) | Jun 2-3 | 2 days | Mineo ChrysaDirector | PPurchase | +3.32K | $22.26 | +$73.9K | New position3.32K after | 2 lots |
| Mar 13, 2025 (view filing) | Mar 11 | 2 days | Ward ShaneCOO & CLO | SSale | −1.66K | $21.96 | −$36.5K | −10.2%14.7K after | |
| Mar 13, 2025 (view filing) | Mar 11 | 2 days | Tari LeslieCHIEF SCIENTIFIC OFFICER | SSale | −1.77K | $21.96 | −$38.9K | −9.9%16.2K after | |
| Sep 13, 2024 (view filing) | Sep 11 | 2 days | Sandison TaylorChief Medical Officer | SSale | −924 | $11.64 | −$10.8K | −3.9%23.1K after | |
| Sep 13, 2024 (view filing) | Sep 11 | 2 days | Tari LeslieCHIEF SCIENTIFIC OFFICER | SSale | −909 | $11.64 | −$10.6K | −4.9%17.8K after | |
| Jun 11, 2024 (view filing) | Jun 7 | 4 days | Stein JeffreyPresident & CEO | PPurchase | +8.00K | $13.21 | +$105.7K | +48.3%24.6K after | |
| Mar 12, 2024 (view filing) | Mar 11 | 1 day | Tari LeslieCHIEF SCIENTIFIC OFFICER | SSale | −21.0K | $0.67 | −$14.1K | −7.5%258.7K after | |
| Mar 12, 2024 (view filing) | Mar 11 | 1 day | Sandison TaylorChief Medical Officer | SSale | −20.7K | $0.67 | −$13.8K | −5.6%347.1K after | |
| Mar 12, 2024 (view filing) | Mar 11 | 1 day | Ward ShaneCOO & CLO | SSale | −20.5K | $0.67 | −$13.7K | −9.3%198.8K after | |
| Mar 12, 2024 (view filing) | Mar 11 | 1 day | Shah PreetamCFO & CBO | SSale | −18.9K | $0.67 | −$12.7K | −7.7%227.2K after | |
| Sep 13, 2023 (view filing) | Sep 11 | 2 days | Tari LeslieCHIEF SCIENTIFIC OFFICER | SSale | −18.5K | $0.95 | −$17.5K | −6.3%275.7K after | |
| Sep 13, 2023 (view filing) | Sep 11 | 2 days | Sandison TaylorChief Medical Officer | SSale | −18.8K | $0.95 | −$17.9K | −4.9%363.8K after | |
| Aug 14, 2023 (view filing) | Aug 14 | Same day | Tari LeslieCHIEF SCIENTIFIC OFFICER | PPurchase | +10.0K | $0.97 | +$9.70K | +3.5%294.2K after | |
| Aug 8, 2023 (view filing) | Aug 8 | Same day | Stein JeffreyPresident & CEO | PPurchase | +50.0K | $0.96 | +$48.0K | +17.8%331.6K after | |
| Mar 27, 2023 (view filing) | Mar 27 | Same day | Stein JeffreyPresident & CEO | PPurchase | +50.0K | $1.04 | +$52.0K | +21.6%281.6K after | |
| Mar 13, 2023 (view filing) | Mar 13 | Same day | Ward ShaneCOO & CLO | SSale | −4.33K | $1.53 | −$6.62K | −4.9%84.6K after | |
| Mar 13, 2023 (view filing) | Mar 13 | Same day | Tari LeslieCHIEF SCIENTIFIC OFFICER | SSale | −7.56K | $1.53 | −$11.6K | −3.8%190.2K after | |
| Mar 13, 2023 (view filing) | Mar 13 | Same day | Shah PreetamCFO & CBO | SSale | −6.65K | $1.53 | −$10.2K | −4.3%148.1K after | |
| Mar 13, 2023 (view filing) | Mar 13 | Same day | Sandison TaylorChief Medical Officer | SSale | −7.20K | $1.53 | −$11.0K | −2.4%288.6K after | |
| Jan 27, 2023 (view filing) | Jan 12 | 15 daysLate | Tari LeslieCHIEF SCIENTIFIC OFFICER | SSale | −11.8K | $1.20 | −$14.2K | −88.8%1.48K after | |
| Sep 19, 2022 (view filing) | Sep 19 | Same day | Shah PreetamCFO & CBO | SSale | −15.6K | $0.77 | −$12.0K | −9.4%150.8K after | |
| Sep 13, 2022 (view filing) | Sep 12 | 1 day | Sandison TaylorChief Medical Officer | SSale | −18.5K | $0.68 | −$12.6K | −6.0%291.8K after | |
| Sep 13, 2022 (view filing) | Sep 12 | 1 day | Tari LeslieCHIEF SCIENTIFIC OFFICER | SSale | −18.2K | $0.68 | −$12.3K | −8.6%193.7K after | |
| Sep 13, 2022 (view filing) | Sep 12 | 1 day | Daruwala PaulChief Operating Officer | SSale | −16.2K | $0.68 | −$11.0K | −6.8%221.1K after | |
| Mar 23, 2022 (view filing) | Mar 21 | 2 days | Johnson BradyVice President, Finance | SSale | −654 | $0.81 | −$529.74 | −1.3%49.4K after | |
| Mar 11, 2022 (view filing) | Mar 11 | Same day | Johnson BradyVice President, Finance | SSale | −945 | $0.71 | −$670.95 | −1.9%50.0K after | |
| Jan 7, 2022 (view filing) | Jan 5 | 2 days | Daruwala PaulChief Operating Officer | SSale | −5.13K | $1.25 | −$6.42K | −2.7%187.3K after | |
| Jan 7, 2022 (view filing) | Jan 5 | 2 days | Johnson BradyVice President, Finance | SSale | −416 | $1.25 | −$520 | −0.8%51.0K after | |
| Jan 7, 2022 (view filing) | Jan 5 | 2 days | Tari LeslieChief Scientific Officer | SSale | −1.25K | $1.25 | −$1.56K | −0.8%155.4K after | |
| Nov 15, 2021 (view filing) | Nov 12 | 3 days | Stein JeffreyPresident & CEO | PPurchase | +50.0K | $1.59 | +$79.5K | +12.0%465.9K after | |
| Nov 15, 2021 (view filing) | Nov 12 | 3 days | Shah PreetamCFO & CBO | PPurchase | +20.0K | $1.54 | +$30.8K | New position20.0K after | |
| Sep 14, 2021 (view filing) | Sep 13 | 1 day | Franson Timothy RDirector | PPurchase | +7.00K | $2.12 | +$14.8K | +175.0%11.0K after | |
| Aug 19, 2021 (view filing) | Aug 18-19 | 1 day | Stein JeffreyPresident & CEO | PPurchase | +50.0K | $1.73 | +$86.7K | +13.7%415.9K after | 2 lots |